Alessandro Tafuri1,2,3, Michele Marchioni4, Clara Cerrato5, Andrea Mari6, Riccardo Tellini6, Katia Odorizzi5, Alessandro Veccia7, Daniele Amparore8, Aliasger Shakir9, Umberto Carbonara10, Andrea Panunzio5, Federica Trovato11, Michele Catellani12, Letizia M I Janello12, Lorenzo Bianchi13, Giacomo Novara14, Fabrizio Dal Moro14, Riccardo Schiavina13, Elisa De Lorenzis15, Paolo Parma7, Sebastiano Cimino11, Ottavio De Cobelli12, Francesco Maiorino16, Pierluigi Bove16, Fabio Crocerossa17, Francesco Cantiello17, David D'Andrea18, Federica Di Cosmo19, Francesco Porpiglia8, Pasquale Ditonno10, Emanuele Montanari15, Francesco Soria20, Paolo Gontero20, Giovanni Liguori21, Carlo Trombetta21, Guglielmo Mantica22, Marco Borghesi22, Carlo Terrone22, Francesco Del Giudice23, Alessandro Sciarra23, Andrea Galosi24, Marco Moschini25, Shahrokh F Shariat18, Marta Di Nicola26, Andrea Minervini6, Matteo Ferro12, Maria Angela Cerruto5, Luigi Schips4, Vincenzo Pagliarulo19, Alessandro Antonelli27. 1. Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Stefani 1, 37126, Verona, Italy. tafuri.alessandro@gmail.com. 2. Department of Urology, "Vito Fazzi" Hospital, Lecce Piazza Filippo Muratore, 1, 73100, Lecce, Italy. tafuri.alessandro@gmail.com. 3. Department of Neuroscience, Imaging and Clinical Sciences, G. D'Annunzio University, Chieti, Italy. tafuri.alessandro@gmail.com. 4. Department of Urology, University of Chieti, Chieti, Italy. 5. Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Stefani 1, 37126, Verona, Italy. 6. Department of Urology, University of Florence, Florence, Italy. 7. Department of Urology, Mantua Hospital, Mantua, Italy. 8. School of Medicine, Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy. 9. Keck School of Medicine, Institute of Urology, University of Southern California, Los Angeles, CA, USA. 10. Department of Urology, Aldo Moro University, Bari, Italy. 11. Department of Surgery, Urology Section, University of Catania, Catania, Italy. 12. Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy. 13. Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 14. Unit of Urology, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy. 15. Department of Urology, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. 16. Urology Unit, San Carlo di Nancy Hospital - GVM Care and Research, Rome, Italy. 17. Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. 18. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 19. Department of Urology, "Vito Fazzi" Hospital, Lecce Piazza Filippo Muratore, 1, 73100, Lecce, Italy. 20. Division of Urology, Department of Surgical Sciences - Urology, Città della Salute e della Scienza di Torino - Molinette Hospital, University of Turin, Turin, Italy. 21. Department of Urology, University of Trieste, Cattinara Hospital - ASUGI, Trieste, Italy. 22. Department of Urology, Policlinico San Martino Hospital, University of Genova, Genoa, Italy. 23. Department of Maternal-Infant and Urological Sciences, Sapienza/Policlinico Umberto I, Rome, Italy. 24. Department of Urology, University of Ancona, Ancona, Italy. 25. Division of Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. 26. Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti, Chieti, Italy. 27. Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Stefani 1, 37126, Verona, Italy. alessandro.antonelli@univr.it.
Abstract
PURPOSE: To investigate prevalence and predictors of renal function variation in a multicenter cohort treated with radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). METHODS: Patients from 17 tertiary centers were included. Renal function variation was evaluated at postoperative day (POD)-1, 6 and 12 months. Timepoints differences were Δ1 = POD-1 eGFR - baseline eGFR; Δ2 = 6 months eGFR - POD-1 eGFR; Δ3 = 12 months eGFR - 6 months eGFR. We defined POD-1 acute kidney injury (AKI) as an increase in serum creatinine by ≥ 0.3 mg/dl or a 1.5 1.9-fold from baseline. Additionally, a cutoff of 60 ml/min in eGFR was considered to define renal function decline at 6 and 12 months. Logistic regression (LR) and linear mixed (LM) models were used to evaluate the association between clinical factors and eGFR decline and their interaction with follow-up. RESULTS: A total of 576 were included, of these 409(71.0%) and 403(70.0%) had an eGFR < 60 ml/min at 6 and 12 months, respectively, and 239(41.5%) developed POD-1 AKI. In multivariable LR analysis, age (Odds Ratio, OR 1.05, p < 0.001), male gender (OR 0.44, p = 0.003), POD-1 AKI (OR 2.88, p < 0.001) and preoperative eGFR < 60 ml/min (OR 7.58, p < 0.001) were predictors of renal function decline at 6 months. Age (OR 1.06, p < 0.001), coronary artery disease (OR 2.68, p = 0.007), POD-1 AKI (OR 1.83, p = 0.02), and preoperative eGFR < 60 ml/min (OR 7.80, p < 0.001) were predictors of renal function decline at 12 months. In LM models, age (p = 0.019), hydronephrosis (p < 0.001), POD-1 AKI (p < 0.001) and pT-stage (p = 0.001) influenced renal function variation (ß 9.2 ± 0.7, p < 0.001) during follow-up. CONCLUSION: Age, preoperative eGFR and POD-1 AKI are independent predictors of 6 and 12 months renal function decline after RNU for UTUC.
PURPOSE: To investigate prevalence and predictors of renal function variation in a multicenter cohort treated with radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). METHODS: Patients from 17 tertiary centers were included. Renal function variation was evaluated at postoperative day (POD)-1, 6 and 12 months. Timepoints differences were Δ1 = POD-1 eGFR - baseline eGFR; Δ2 = 6 months eGFR - POD-1 eGFR; Δ3 = 12 months eGFR - 6 months eGFR. We defined POD-1 acute kidney injury (AKI) as an increase in serum creatinine by ≥ 0.3 mg/dl or a 1.5 1.9-fold from baseline. Additionally, a cutoff of 60 ml/min in eGFR was considered to define renal function decline at 6 and 12 months. Logistic regression (LR) and linear mixed (LM) models were used to evaluate the association between clinical factors and eGFR decline and their interaction with follow-up. RESULTS: A total of 576 were included, of these 409(71.0%) and 403(70.0%) had an eGFR < 60 ml/min at 6 and 12 months, respectively, and 239(41.5%) developed POD-1 AKI. In multivariable LR analysis, age (Odds Ratio, OR 1.05, p < 0.001), male gender (OR 0.44, p = 0.003), POD-1 AKI (OR 2.88, p < 0.001) and preoperative eGFR < 60 ml/min (OR 7.58, p < 0.001) were predictors of renal function decline at 6 months. Age (OR 1.06, p < 0.001), coronary artery disease (OR 2.68, p = 0.007), POD-1 AKI (OR 1.83, p = 0.02), and preoperative eGFR < 60 ml/min (OR 7.80, p < 0.001) were predictors of renal function decline at 12 months. In LM models, age (p = 0.019), hydronephrosis (p < 0.001), POD-1 AKI (p < 0.001) and pT-stage (p = 0.001) influenced renal function variation (ß 9.2 ± 0.7, p < 0.001) during follow-up. CONCLUSION: Age, preoperative eGFR and POD-1 AKI are independent predictors of 6 and 12 months renal function decline after RNU for UTUC.
Authors: Morgan Rouprêt; Marko Babjuk; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Nigel C Cowan; Jose L Dominguez-Escrig; Paolo Gontero; A Hugh Mostafid; Joan Palou; Benoit Peyronnet; Thomas Seisen; Viktor Soukup; Richard J Sylvester; Bas W G van Rhijn; Richard Zigeuner; Shahrokh F Shariat Journal: Eur Urol Date: 2020-06-24 Impact factor: 20.096
Authors: Aristotle Bamias; Lia A Moulopoulos; Aggelos Koutras; Gerassimos Aravantinos; George Fountzilas; Dimitris Pectasides; Efstathios Kastritis; Dimitros Gika; Dimosthenis Skarlos; Helena Linardou; Haralambos P Kalofonos; Meletios A Dimopoulos Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Matthew D Galsky; Noah M Hahn; Jonathan Rosenberg; Guru Sonpavde; Thomas Hutson; William K Oh; Robert Dreicer; Nicholas Vogelzang; Cora N Sternberg; Dean F Bajorin; Joaquim Bellmunt Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544
Authors: Francesco Soria; Shahrokh F Shariat; Seth P Lerner; Hans-Martin Fritsche; Michael Rink; Wassim Kassouf; Philippe E Spiess; Yair Lotan; Dingwei Ye; Mario I Fernández; Eiji Kikuchi; Daher C Chade; Marko Babjuk; Arthur P Grollman; George N Thalmann Journal: World J Urol Date: 2016-09-07 Impact factor: 4.226
Authors: Pierre Colin; Philippe Koenig; Adil Ouzzane; Nicolas Berthon; Arnauld Villers; Jacques Biserte; Morgan Rouprêt Journal: BJU Int Date: 2009-08-18 Impact factor: 5.588
Authors: Alessandro Tafuri; David D Smith; Giovanni E Cacciamani; Sarah Cole; Aliasger Shakir; Sarmad Sadeghi; Nicholas J Vogelzang; David Quinn; Parkash S Gill; Inderbir S Gill Journal: Clin Genitourin Cancer Date: 2020-01-31 Impact factor: 3.121
Authors: Jeffrey J Leow; Yew Lam Chong; Steven L Chang; Begoña P Valderrama; Thomas Powles; Joaquim Bellmunt Journal: Eur Urol Date: 2020-08-12 Impact factor: 20.096